Biogen Inc [BIIB]
$233.63 0.01 (0.00%)
Market Cap 44.87 Billion
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
EPS 7.17 P/E Ratio 10.77
Previous Earnings Wed, Apr 24, 2019
Latest Earnings Tue, Jul 23, 2019 (In 7 days)
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.